Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Candel Therapeutics, Inc. (CADL : NSDQ)

• Company Description    Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass. Number of Employees: 65

• Price / Volume Information    Yesterday's Closing Price: $4.00 Daily Weekly Monthly 20 Day Moving Average: 95,369 shares Shares Outstanding: 28.69 (millions) Market Capitalization: $114.77 (millions) Beta: 52 Week High: $14.78 52 Week Low: $3.33 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -22.93% -15.87% 12 Week -4.99% 2.69% Year To Date -48.85% -39.41%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 117 KENDRICK STREET SUITE 450 - NEEDHAM,MA 02494 USA ph: 617-916-5445 fax: - investors@candeltx.com http://www.candeltx.com

• General Corporate Information    Officers Paul Peter Tak - President and Chief Executive Officer Paul B Manning - Chairman John Canepa - Chief Financial Officer Edward J. Benz Jr - Director Chris Martell - Director Peer Information Candel Therapeutics, Inc. (CORR.) Candel Therapeutics, Inc. (RSPI) Candel Therapeutics, Inc. (CGXP) Candel Therapeutics, Inc. (BGEN) Candel Therapeutics, Inc. (GTBP) Candel Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 137404109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 09/14/22 Share - Related Items Shares Outstanding: 28.69 Most Recent Split Date: (:1) Beta: Market Capitalization: $114.77 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.48 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.91 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/14/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.80 Price/Cash Flow: - Price / Sales: 925.58 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -160.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 0.00% ROE 03/31/22 - -29.17 12/31/21 - -68.49 09/30/21 - - ROA 03/31/22 - -13.57 12/31/21 - -26.63 09/30/21 - - Current Ratio 03/31/22 - 17.48 12/31/21 - 15.84 09/30/21 - 20.68 Quick Ratio 03/31/22 - 17.48 12/31/21 - 15.84 09/30/21 - 20.68 Operating Margin 03/31/22 - - 12/31/21 - -11,591.94 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - -29,132.26 09/30/21 - - Pre-Tax Margin 03/31/22 - -34,967.74 12/31/21 - -28,899.20 09/30/21 - - Book Value 03/31/22 - 2.22 12/31/21 - 2.24 09/30/21 - 2.20 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.32 12/31/21 - 0.01 09/30/21 - 0.01 Debt-to-Capital 03/31/22 - 24.35 12/31/21 - 0.87 09/30/21 - 0.85

Powered by Zacks Investment Research ©